
In a study of 312 cystic fibrosis patients, ETI therapy significantly reduced annual antibiotic courses (2.5 to 0.7, p<0.001) and IV antibiotic use (59% to 38%, p<0.001). While Pseudomonas aeruginosa, Burkholderia, and Stenotrophomonas prevalence declined, fluoroquinolone resistance in P. aeruginosa increased. Resistant bacteria pre-ETI were more likely to persist, highlighting the need for continued antimicrobial resistance monitoring.
Like
Save
Share